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Consolidated knowledge is accumulating as to the role of epigenetic regulatory mechanisms in the physiology of
vascular development and vascular tone as well as in the pathogenesis of cardiovascular disease. The modulation of
gene expression through modification of the epigenome by structural changes of the chromatin architecture
without alterations of the associated genomic DNA sequence is part of the cellular response to environmental
changes. Such environmental conditions, which are finally being translated into adaptations of the cardiovascular
system, also comprise pathological conditions such as atherosclerosis or myocardial infarction. This review
summarizes recent findings on the epigenetics of vascular regulation and disease and presents nutritional and
pharmacological approaches as novel epigenetic strategies in the prevention and treatment of cardiovascular
disease.
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Epigenetic alterations are chromatin-based modifications
that affect the expression of genes without altering the
DNA sequence itself. Such modifications include the
methylation of DNA, the posttranslational modification of
histone proteins and RNA-based mechanisms, [1] which
may altogether modulate the tertiary structure and thus the
accessibility of promoter DNA for transcription factors and
numerous regulatory elements that finally affect transcrip-
tion [2]. Epigenetic processes are essential as to the deter-
mination of cell identity and for the propagation of
modifications that are meiotically and mitotically heritable
[3]. In this context, epigenetic pathways are key elements in
the regulation of endothelial gene expression, and thus in
the pathogenesis of vascular disease such as atherosclerosis
and vascular restenosis. The vascular system is highly flex-
ible with regard to physiological and pathological challenges
and carries therefore the potential to regenerate and gener-
ate new structures during the whole organismal life span on
the basis of two major epigenetic principles: the heritable
propagation of the information on changes in gene* Correspondence: mahlknecht@k-plus.de
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reproduction in any medium, provided the origexpression without alterations in the DNA sequence, and
the capacity to develop different phenotypes from one single
genotype [4].Epigenetic regulation - overview
Since Conrad Waddington first coined the term “epigen-
etics” back in 1942 as the study about “the causal inter-
actions between genes and their products, which bring
the phenotype into being”, research progress since then
led to an advanced definition [5]. More recently, epigen-
etics was redefined as the study of “stable alterations in
gene expression without alterations in the genetic code
itself” [6]. These alterations in gene expression are
achieved by changes in the tertiary structure of the DNA
strand and thus the accessibility of the DNA for mole-
cules which effect gene expression. Under physiological
conditions this machinery allows relatively fast heritable
changes in gene expression in response to environmental
factors such as nutrition or lifestyle conditions and plays
a pivotal role in embryogenesis and genomic imprinting.
Accordingly, the addition of activating or repressive epi-
genetic marks affects gene expression. The permanent si-
lencing of one X-chromosome in women as an example
is explained by heavy genomic DNA hypermethylation of
CpG islands [7]. Significant alterations of the epigenome
may be found in numerous diseases such as asthma ortral Ltd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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which highlights the potential of epigenetic modifications
on the development of novel epigenetic treatment
strategies.
The tertiary DNA structure is composed of chromatin, a
complex of DNA, histones and other chromosomal pro-
teins. The nucleosome is the fundamental component of
chromatin and consists of a protein octamer that contains
two copies of each of the histone proteins H2A, H2B, H3
and H4 with and 146 base pairs of DNA, which are being
wound around this protein core [2]. Such a fibre of se-
quentially arrayed nucleosomes and linker histone proteins
is preferentially arranged into a stable 30 nm solenoid ter-
tiary structure, which is itself the basis for stable higher
order chromatin compaction [8]. The degree of chromatin
condensation is reversibly regulated by epigenetic mechan-
isms and thus, chromatin may principally be found in two
variants: euchromatin and heterochromatin. Euchromatin
stands for decondensed chromatin, i.e. transcriptionally
active chromatin. Heterochromatin on the other hand,
describes highly condensed and therefore transcriptionally
inactive chromatin [2] Activating epigenetic marks are
therefore predominantly found on euchromatin, while het-
erochromatin is primarily associated with repressive epi-
genetic marks [9].
DNA methylation
DNA methylation is one of the fundamental epigenetic
marks that is associated with transcriptional silencing,
and plays a key role not only in X-chromosomal inactiva-
tion, but also in embryonic development, genomic
imprinting, and lineage specification [1,10,11]. In mam-
mals, DNA methylation takes place mostly within CpG
dinucleotides, where a methyl group that is derived from
S-adenosyl-L-methionine is bound in position 5 within
the cytosine ring, thus forming 5-methyl-cytosine [4,11].
This pyrimidine can still constitute a base pair with
guanine [1]. In healthy somatic cells, up to 90% of CpG
dinucleotides, i.e. 3% to 6% of all cytosines, are methy-
lated, except for promoter CpG islands, which appear to
be protected from methylation [7,11].
So far, three active DNA methyltransferases (DNMTs),
which catalyse the methylation of mammalian DNA cyto-
sines in position C5, have been described: DNMT1,
DNMT3a, and DNMT3b [1] DNMT3L which belongs to
the group of DNMT proteins lacks the catalytic activity it-
self, but is required for the enzymatic activities of DNMT3A
and DNMT3B [12] DNMT2 is a highly conserved protein
and shows a strong tRNA methyltransferase activity. It is
known to methylate aspartic acid transfer RNA without
being restricted to this process [13]. Amino acid methyla-
tion of arginine and lysine residues of proteins is usually
carried out by peptilarginine or lysine methyltransferases,
respectively. During embryonic development, DNMT3aand DNMT3b are responsible for de novo methylation, and
for the creation of specific DNA methylation patterns [11].
While DNMT3a is essential in the context of genomic
imprinting during gametogenesis, [14-16]. DNMT3b plays
an important role during embryonic development [15].
DNMT1 is required for the maintenance and propagation
of DNA methylation patterns across generations of cells, i.e.
the methylation pattern is carried along the replication
process during mitotic cell division [1]. DNMT1 is however
not that efficient as to the maintenance of methylation pat-
terns within CpG dense regions [11] and during massive
demethylation events such as after fertilization, [14] which
may as a consequence lead to alterations of the original
methylation pattern. Three principal mechanisms are
involved in the regulation of gene repression via 5-methyl-
cytosine: First, 5-methyl-cytosine can sterically affect tran-
scription factors to their cis-DNA binding elements, as it is
described for several transcription factors [17-20]. During
this process, methyl groups of methylated CpG dinucleo-
tides intercalate into the major groove of the DNA helix [1].
Second, methyl-CpG binding proteins such as MeCP2,
interfere with the recruitment of transcription factors (i.e.
DNA-binding trans factors) [2]. Third, these methyl-CpG
binding proteins are able to recruit large protein complexes
which control the accessibility of DNA through modifica-
tion of the chromatin structure [11]. On the other hand, a
transcriptional activator, human CpG binding protein
(hCGBP), has been reported that specifically recognizes and
binds unmethylated GpG dinucleotides [21]. Even though,
both, active (replication-independent), as well as passive
(replication-dependent) mechanisms have been described,
the process as of how DNA methylation marks are exactly
removed, is still unexplained [11]. Therapeutically, nucleo-
side analogues require proliferating cells in order to inhibit
DNA methylation, because the nucleoside analogues exert
their activity through an irreversible covalent bond with
DNMTs after their incorporation into DNA [7].Histone proteins
The histone proteins within the nucleosomal core consist
of a globular domain and an N-terminal tail, which may
be subjected to more than 60 variations of posttransla-
tional modification [2] .Lysine for example, can be modi-
fied by acetylation, methylation, ubiquitylation or
sumoylation, while arginine can be modified solely by
methylation; and finally serine and threonine by phos-
phorylation [10,22]. In contrast to DNA methylation,
most histone posttranslational modifications are highly
dynamic processes [1]. Even though some of these cova-
lent modifications take place within the histone globular
domains, the best studied modifications – and more spe-
cifically the effects of lysine acetylation and methylation
on chromatin condensation and thus on the regulation
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N-terminal tails [10,22,23].
Histone acetylation
Histone acetylation goes along with transcriptional activa-
tion and is mediated by histone acetyltransferases (HATs),
[1,2,24] while it is antagonized by the opposing histone
deacetylase (HDAC) enzymatic activity, which mediates
the removal of acetyl groups and therefore goes along with
chromatin compaction and transcriptional inactivation.
HDACs are grouped into four classes according to their
relationship to their homologues in S. cerevisiae: class I
(HDAC1-3, HDAC8), class II (HDAC4-7, HDAC 9–10),
class III sirtuins (SIRT1-7), and class IV (HDAC11) [22].
With the exception of class III HDACs – sirtuins, which
are NAD+-dependent, all other HDACs are Zn2+
dependent. Both, HATs and HDACs unspecifically influ-
ence the acetylation status of proteins. Their specificity as
to the posttranslational modification of histone proteins
may – at least in part - be achieved through their recruit-
ment to chromatin within multi-protein complexes, [22]
and their localization within specific cellular compart-
ments. Massive acetylation of lysine residues may activate
transcription through neutralization of the basic charge of
these residues and through the recruitment of bromodo-
main-containing protein complexes, which may include
other HATs and chromatin remodeling enzymes [25]. This
process goes along with an easily accessible chromatin
configuration, so that transcription is facilitated [26]. The
acetyl groups that are needed for this process are trans-
ferred from acetyl-coenzyme A complexes, and the reac-
tion is catalyzed by three principal families of HATs: CBP/
p300, GNAT and MYST [1]. The different families of
mammalian HDACs are grouped in four classes: class I
(HDAC1-3, HDAC8), class II (HDAC4-7, HDAC 9–10),
class III sirtuins (SIRT1-7), and class IV (HDAC11)
[22,27,28].
Histone methylation
Unlike the acetylation of histone proteins, the methylation
of histone lysine and/or arginine residues has variable
effects on gene expression. The methylation of histone ly-
sine residues has been extensively studied and in fact, the
effect on gene expression very much depends on the spe-
cific lysine residue that is being modified. Also, the single
lysine residues can be variably methylated to mono-, di-
and trimethylated states [2,29,30]. Every such status is es-
sential and allows a highly specific distinction concerning
the methylation pattern: active promoters for example, are
enriched in trimethylated H3 lysine 4 (H3K4) residues,
whereas enhancer elements are enriched in monomethy-
lated H3K4 residues [31]. On the other hand, di- and tri-
methylated histone H3 lysine 9 (H3K9) residues are
strongly correlated with transcriptional repression [22,32].Enzymes that catalyze this reaction, act dynamically as ei-
ther histone methyltransferases or histone demethylases. e.
g. lysine-specific histone demethylase 1 which demethy-
lases H3K4 or Jumonji C (JmjC)-domain-containing family
of proteins which catalyse demethylation of H3K4me3
[29]. Few lysine residues can be either methylated or
modified by acetylation, but never both together [2].
RNA-based mechanisms
So far, the RNA-based mechanisms are the least well
understood mechanisms of epigenetic regulation. Non-
coding RNA (ncRNA) appear to be involved in the chro-
matin-based regulation of gene expression [2,6,33]. In
fact there is increasing evidence that RNA-based
mechanisms combine the coordinated activities of this
noncoding RNA together with other epigenetic modifica-
tions, such as DNA methylation and posttranslational
histone modifications. For example the RNA-induced
initiation of transcriptional gene silencing complex
(SISC) forms heterochromatic sites as a consequence of
histone methylation[34]. Similarly, the expression of
ncRNA itself may be modulated through epigenetic
mechanisms: miRNA 124 for instance, is silenced in dif-
ferent types of cancer by DNA-methylation. These are
only two examples for the complexity and intertwine-
ment of epigenetic mechanisms. NcRNAs are defined by
their number of nucleotides: Short ncRNAs count up to
200 nucleotides long ncRNAs count more than 200
nucleotides [2]. These ncRNAs seem to regulate the
chromatin compaction state of defined genomic loci
[35]. Large intervening non-coding RNAs (lincRNAs) are
able to recruit chromatin modifying complexes and/or to
overlap the coding region of genes and thus to regulate
gene expression at the level of specific target loci [2,36].
As an example, Khalil et al. found about 20% of 3,300
human long intergenic ncRNAs were bound by Poly-
comb Repressive Complex 2 (PRC2) or other chromatin-
modifying complexes [36]. In addition, long ncRNAs
(>200 nucleotides) are able to mediate transcriptional
activation by recruiting the H3K4 mixed-lineage
leukemia methyltransferase (MLL1) [35]. Small non-cod-
ing RNAs on the other hand, are ~21 bp long with target
messengers that can induce degradation of the dsRNA
complex through the action of the RNA III endonuclease
(also referred to as “Dicer”) [37]. The transcriptional si-
lencing by small ncRNAs like microRNAs (miRNA) and
short interfering RNAs (siRNA) is currently being inves-
tigated very intensively due to their promising thera-
peutic potential. These small RNAs are grouped into
different classes depending on their length and function
[38]. They are able to specifically inhibit target mRNAs
of different genes. MiRNAs and siRNAs are 21 to 26
nucleotides long, and are well-known mediators of tis-
sue-specific posttranscriptional gene silencing as a part
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(scrambled inhibitory RNA) respectively [1,37] miRNAs
are synthesized by RNA polymerase II as a long RNA
primary transcript (pri-miRNA) and cleaved by Drosha,
the double-stranded RNA endonuclease III, to produce a
typical stem-loop structure, known as a pre-miRNA [39].
The nuclear RNase III Drosha initiates microRNA pro-
cessing [39]. Drosha is part of a multi-protein complex,
which contains the double-stranded RNA binding pro-
tein Pasha also known as DGCR8 [40]. Pasha binds sin-
gle-stranded pri-miRNA fragments and stabilizes them
for processing by Drosha. Additional enzymes that pro-
mote the maturation of miRNA are two proteins called
Argonaute and Dicer which are part of RISC. Drosha
and Pasha are both localized within the cell nucleus,
where the processing of pri-miRNA to pre-miRNA takes
place. This pre-miRNA is then exported into the cyto-
plasm via Exportin 5 and then further processed by the
RNase Dicer to dsRNA which is then transported back
into the nucleus via RISC. The mature single strand
(‘guide strand’) is paired to the 3’-untranslated region of
the target RNA and leads to its degradation [41]. SiRNAs
are derived from long double-stranded RNA precursors
and may be found in cells naturally or the may be ex-
ogenously imported and in fact, transcriptional gene si-
lencing can be achieved by exogenously administered
siRNAs directed to promoter regions in mammalian cells
[1]. The mechanisms that are involved herewith are site-
specific DNA methylation [42] and repressive histone
posttranslational modifications [43]. In the future, stud-
ies might demonstrate the far-reaching effects of RNA-
based mechanisms on the regulation of mammalian gene
expression.
Epigenetics of blood vessel physiology
During development and lifelong sustainment of the vas-
cular system epigenetic factors play a crucial role and
permit a high flexibility to sudden physiological changes.
Epigenetic mechanisms in vascularization
After fertilization, the vascular system is one of the first
organ structures that develop. During “vasculogenesis” a
primary capillary plexus is formed de novo from mesoder-
mal cell precursors, while the formation of new vessels
from pre-existing vessels is referred to as “angiogenesis”
and is based on the interaction of pro- and anti-
angiogenic molecules [44]. The initiation of vascular devel-
opment depends on the presence of Fibroblast growth fac-
tors in order to induce hemangioblastic differention. In a
next step vascular endothelial growth factor (VEGF) fur-
ther triggers cell differentiation. The formation of a capil-
lary plexus strongly depends on the expression of adhesion
molecules which form inter-cellular connections such as
VE (vascular endothelial) cadherin, N-cadherin andconnexins, as well as molecules which promote cell matrix
interactions (netrins, semaphorins, fibronectin, integrins)
and a number of signaling pathways that include key pro-
teins such as NOTCH, VEGF1/2, transforming growth fac-
tor beta (TGF-ß), or ephrin type-A receptor 2 (Eph-2) and
4, only to mention a few [45,46]. The acetylation of Notch
via SIRT1 regulates the amplitude and duration of Notch
activity and allows for normal vascular sprouting [47]. In a
second stage, haemodynamic factors and local hypoxia
model the structure, identity and function of the blood
vessels, [48-50] which accentuates the role of epigenetic
mechanisms [4]. In summary, epigenetic mechanisms
strongly influence the development of the vascular system
[1,51].
Vascular development, as well as endothelial and
smooth muscle cell differentiation and function, require
a fine epigenetic adjustment. The promoter regions of
several cell-specific endothelial proteins such as the
endothelial nitric oxide synthase (endothelial isoform of
NO synthase, eNOS [alias: NOS3]) are constitutively ac-
tive [52] and it appears that the key difference to other
cell populations that do not express eNOS is observed at
the chromatin level: while a relaxed and thus transcrip-
tionally permissive chromatin structure may be found at
the level of the eNOS promoter in endothelial cells, this
very locus appears to be highly condensed and thus in a
repressive configuration in non-endothelial cells [2]. In
addition, the expression of the human eNOS-gene is at
least in part, also determined by the DNA methylation
status [53] Matouk et al. proposed that additional chro-
matin-based mechanisms could be relevant for the cell-
specific expression of eNOS. In non-expressing cell
types, the eNOS promoter was hypermethylated and
lacked activating histone posttranslational modifications,
whereas this very promoter was reported to be hypo-
methylated and enriched with activating posttranslational
histone modifications such as acetylated H3K9, H4K12
as well as di- and trimethylated H3K4 in endothelial cells
[53,54]. Endothelial-specific transcription factors such as
KLF2 are also involved in the regulation of the tissue
specific expression of endothelial proteins, [55] more-
over, KLF2 is not even responsible for the differentiation
of precursor cells to endothelium which underlines the
significance of epigenetic regulation [4].
Several studies show that HDAC activity mediates
angiogenesis as a consequence of hypoxia, [56] shear
stress- and VEGF-induced stem cell differentiation
[57,58]. On the other hand the inhibition of HDAC pre-
vents the proliferative response to VEGF [59]. There is
some evidence that the global and endothelial cell-
specific knockout of HDAC 7, a class II HDAC, is asso-
ciated with embryonic lethality and required for the
development of a normal vasculature [60]. HDAC7 is an
important effector molecule in the context of the VEGF-
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ation and subsequent translocation to the cytoplasm inhi-
bits VEGF-mediated proliferation and migration [61].
HDAC activity is known to be critical for the endothelial
differentiation of embryonic stem cells as well as adult
endothelial progenitor cells [57,58,62,63]. Histone acetyl-
ation controls the expression of important signaling mole-
cules like the von-Willebrandt-factor, NOTCH and eNOS
[52]. Nevertheless, for the sprouting process during angio-
genesis, histone methylation appears to be very important
[64].
Several studies correlated environmental stimuli during
development with non-Mendelian diseases, such as cardio-
vascular disease. The persistence and reproducibility of
these studies indicate permanent non-genomic modifica-
tions, which result in a certain cellular “re-programming”.
The modulations needed for this might be based and – at
least in part - explained by epigenetic mechanisms [4].
Such studies show that epigenetic modulations also reflect
environmental signals under physiological and patho-
logical conditions [65,66]. However, only little information
is available on the varying response in foetal endothelial
cells in the context of different pregnancy related diseases
[67,68]. Important evidence for the immediate role of epi-
genetic mechanisms in pathological alterations is found in
diabetes. In this context, it has already been shown how
intra uterine growth restriction (IUGR) generates abnor-
mal programming of gene expression at different levels,
which could advance the development of insulin resistance
and/or type 2 diabetes [4].
Postnatal angiogenesis
During the postnatal period, HDACs have been reported
to be key regulators of angiogenesis [1]. Accordingly,
HDAC inhibitors have already proven to exhibit potent
antiangiogenic activity [69]. Some HDACs appear to have
prominent roles in this context: HDAC1 for example plays
a pivotal role in hypoxia-induced angiogenesis [70]. On
the other hand, specific knockdown of HDAC7 constrains
cell migration and angiogenesis in mature primary endo-
thelial cells in culture [71]. Another important factor in
angiogenic signaling is constituted by SIRT1, a class III
HDAC [72]. SIRT1 is highly expressed during blood vessel
growth and allows for sprouting during angiogenesis
through deacetylation of the forkhead transcription factor
Foxo1 [73].
So far, little information is available on what is going on
within the specific angiogenesis pathways, but it is likely
that the acetylation status of various transcription factors
that are being involved plays an important role [1].
Shear stress
Laminar flow may influence gene regulation via epigen-
etic pathways and thus, disturbed flow is capable ofchanging gene expression in cells [2]. Shear stress for in-
stance, enhances histone H3 K79 methylation in mouse
embryonic stem cells (ESC), [58] where shear stress
causes global histone modification changes and promotes
ESC differentiation to an endothelial cell lineage [58,74].
Accordingly, laminar shear stress also goes along with
both, global and gene-specific histone modifications in
cultured human endothelial cells [75]. Shear stress
enhances the activity of HAT p300 in human endothelial
cells and leads to the acetylation of H3 and H4 at the
level of the eNOS promoter among others [30] HDACs
can also modify gene expression in response to shear
stress for example through the VEGF-signaling pathway:
Zeng et al. showed that HDAC3-mediated p53 deacetyla-
tion and p21 activation caused by shear stress and VEGF
induces differentiation of endothelial cells through the
VEGF receptor 2 (Flk-1)–PI3K–Akt signal pathway [57].
Hypoxia
Intrauterine hypoxia i.e. lower oxygen tension in the
fetus compared to the adult, is to a certain degree essen-
tial for cardiac formation. Hypoxia decreases global gene
expression via epigenetic pathways: A global decrease in
H3K9 acetylation can be observed in various types of
cells as a consequence of increased HDAC activity
[76,77]. On the other hand, acetylated H3K9 is found at
the promoter level for hypoxia activated genes such as
VEGF [76-78]. Increasing evidence also accumulates that
the hypoxia- inducible factor (HIF-1α) is involved in the
maintenance of global transcriptional silencing, as well
as in directing gene repression to specific genes [79,80]
Kato et al. showed that HDAC7 is transported to the nu-
cleus together with HIF-1α under hypoxic conditions
where it upregulates the transcriptional activity of HIF-
1α forming a complex together with p300 [80]. In con-
clusion, the current understanding of hypoxia-induced
epigenetic changes is comparatively poor and needs fur-
ther investigation.
Cardiovascular disease
In the past few years, there has been increasing evidence
that part of the gene-environmental interactions is regu-
lated by epigenetic mechanisms. Accordingly, abnormal
regulation in this context can result in complex diseases.
Atherosclerosis and restenosis
Some of the genes that are regulated by epigenetic modifica-
tion constitute a major part of the regulatory work of extra-
cellular matrix formation, inflammation and proliferation,
which are involved in cardiovascular pathology including
atherosclerosis and restenosis [3]. Both, atherosclerosis and
restenosis are intensively affected by the inflammatory re-
sponse to endothelial injury and the subsequent reshaping
of the vessel wall in size and composition, also referred to
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proliferation and migration of vascular smooth muscle cells
(VSMCs) and the formation of extracellular matrix, leads to
an accumulation of collagen and proteoglycans, which fi-
nally results in to the occlusion of blood vessels [3]. For ath-
erosclerosis, elevated lipoprotein levels and cigarette smoke
are a main effectors, [83] while restenosis is mainly an over-
shooting wound healing process in response to vascular in-
jury by balloon dilation or stent placement. Atherosclerosis
develops from the accumulation of oxidized lipoproteins
within foam cells and extracellularly together with the pro-
liferation of arterial smooth muscle cells. The incidence of
atherosclerosis is associated with increasing age, whereas re-
stenosis is develops rapidly after interventions of revascular-
ization [3] Global DNA hypermethylation appears to be
significantly associated with vascular inflammatory response
to endothelial injury and correlates with cardiovascular
mortality [84] The underlying mechanisms that lead to in-
flammation are believed to be based on the inactivation of
suppressors of cytokine signaling (SOCS) [85]. Athero-
sclerosis and restenosis are worsened as a consequence of
multiple inflammatory pathways, which are regulated by
pro-inflammatory transcription factors like NFκ-B
[3,86]. The activity of NFκB is known to be regulated
through posttranslational acetylation, i.e. by HATs and
HDACs [87]. Eotaxin, which is a chemoattractant for eo-
sinophilic granulocytes, is an important player in theHATs
HDACs
NFκ-B
Figure 1 Pathogenesis of Atherosclerosis. Injury of vascular epithelium b
leads to inflammation of tissue and global DNA-methylation within the cell
subsequently and expression of endothelial adhesion molecules leads to m
LDLs and become foam cells (forming of atherom). The forming of an athe
smooth muscle cells (SMCs) and the accumulation of collagens and proteocontext of inflammatory response and appears to be a
target of epigenetic regulation: inflammatory signaling
via TNF-α specifically leads to histone H4 acetylation
and induces the binding of p65 to the eotaxin promoter,
which induces transcription of the eotaxin gene and
consequently, increasing numbers of inflammatory cells
are being recruited and activated within the atheroma-
tous plaque (Figure 2) [88,89]. Another factor that plays
an important role in atherosclerosis and restenosis is the
granulocyte macrophage colony-stimulating factor
(GM-CSF). In a rabbit model, GM-CSF injections have
been shown to reduce the formation of neointima and in
accordance with a patient study, NFκB-mediated inflamma-
tory signaling concurs with histone H4 hyperacetylation,
which correlates with increased GM-CSF expression levels
[3,90]. The predominant finding in this study was a reduc-
tion in the progression of artherosclerosis by GM-CSF.
Furthermore the HDAC inhibitor trichostatin A (TSA)
increases the expression of GM-CSF in alveolar macro-
phages and airway epithelial cell lines after activation
with inflammatory stimuli, [91-93] which suggests that
the signalling pathway that involves GM-CSF could
affected by alterations at the epigenomic level. Numer-
ous other factors such as cyclooxygenase-2 do also ap-
pear to be regulated via epigenetic modifications. Taken
together, epigenetic modulation seem to play a key role
in the regulation of inflammatory events and couldy oxidized low density lipoproteins (oxidized LDL) or cigarette smoke
s. Proinflammatory transcription factors like NFκ-B are activated
onocyte adhesion. These cells incooperate large quantities of oxidize d
rosclerotic plaque is accompanied by the invasion of the vessel wall by
glycans (Rebuilding of vessel wall).
Figure 2 Epigenetic modulation of Eotaxin expression via NFκ-B. Inflammatory signalling via TNF-α leads to acetylation of histone H4 and
induces the binding of p65 subunit of NFκB-complex to unmethylated sites of the eotaxin promoter. Transcription of the eotaxin gene is induced
and consequently the number of inflammatory cells which are recruited and activated within the atherosclerotic plaque.
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therapy.Myocardial infarction
In a murine model of ischemia and reperfusion, ischemia
was shown to induce HDAC activity in the heart and
consequently deacetylation of histones H3 and H4 [94].
From 1 h prior to ischemia until 45 min after reperfu-
sion, the HDAC inhibitors TSA and scriptaid were able
to reverse the activity of ischemia-induced HDACs
in vivo and to reduce myocardial infarct size by up to
50%. In an in vitro study, it has been shown that a 5 h
period of hypoxia resulted in a strong decrease in acety-
lated H3 and H4 histones in mouse cardiomyocytes,
which was completely blocked by TSA [94]. In 2002 Mc
Kinsey et al. found that class IIa HDACs (i.e. HDAC4,
-5, -7, and −9) interact with members of the myocyte en-
hancer factor-2 (MEF2) transcription factor family which
are key regulators of cardiac hypertrophy. Therefore, the
down regulation of these HDACs raises new possibilities
as to cardiovascular disease treatment and prevention
[95] Zhang et al. demonstrated that the inhibition of his-
tone deacetylases (HDAC) protects the heart against is-
chemia-reperfusion (I/R) injury in which the acetylation
of NFκBp50 plays the pivotal role [96]. In summary, epi-
genetic pathways play an important role in myocardial
infarction, and HDAC inhibitors could therefore opennew horizons as to improved individualized treatment
strategies in the future.Abdominal aortic aneurysm
Abdominal aortic aneurysm (AAA) appears to be the re-
sult of an imbalance between aortic extracellular matrix
destructive and restorative processes [8]. In this context,
the normal lamellar architecture of the aorta gets
destroyed and is subsequently invaded by inflammatory
cells, including T/B lymphocytes, macrophages, neutro-
phils, mast cells and plasma cells [97]. In animal models,
AAA have been shown to be a dynamic remodelling
process, with neovascularisation, inflammatory cell infil-
tration, endothelial dysfunction, apoptosis and depletion
of the vascular smooth muscle cells, as well as destruc-
tion of the elastic media [98]. The pathogenesis of AAA
is poorly understood, and there seem to be multiple en-
vironmental and genetic factors which cause the initi-
ation and progression of AAA. Many of the AAA risk
factors including cigarette smoke, older age, male gender
and hypertension, have already been linked to epigenetic
effects and could promote AAA. Previous investigations
demonstrated that persistent inflammation in the context
of atherosclerosis might lead to aberrant DNA methyla-
tion as well as alterations in histone modification. Given
that AAA has a strong inflammatory component, it is
likely that epigenetic mechanisms are involved in the
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matrix metalloproteinase-2 and 9 (MMP) whose proteo-
lytic activity contributes to matrix degradation in AAA,
are significantly upregulated and the expression of these
MMPs is in fact regulated by posttranslational acetyl-
ation at the histone level [8,99,100].
Raynaud’s syndrome
Even more than 100 years after its first description, the
pathogenesis of Raynaud’s syndrome is still quite unclear
[101,102]. The interaction of different regulatory mechan-
isms between endothelium, smooth muscle and autonomic
and sensory innervation, which ultimately lead to the
pathological vasospasm of this disease, is extremely com-
plex and affects both, endothelium-dependent and endo-
thelium-independent mechanisms of vasoregulation. The
endothelial vasoregulation is based on the interplay be-
tween opposing vasoconstrictive mediators (e.g. plasma
endothelin-1 [EDN1], thromboxane [TXA 2], methyl ar-
ginine, transcription factor HIF-1α [hypoxia-inducible
factor 1-alpha] and acetylcholine) and vasodilating
agents (e.g. prostaglandin [prostacyclin], CGRP [calci-
tonin gene-related peptide] and eNOS [102-104]. The
activity of eNOS - as an example for a gene that is being
regulated at the epigenomic level - can be reduced by
histone deacetylase (HDAC) inhibitors, which conse-
quently results in reduced vasorelaxation [52]. Further-
more, there are direct interactions between epigenetic
regulators and proteins, being involved in the regulation
of the vascular tone, e.g. the transcription factor HIF-1α,
which interacts directly with histone deacetylases [80].
Importance of NO, NADPH/NADH oxidase in the
modulation of vascular tone
The vascular endothelium is not only a structural semi-
selective diffusion barrier between the vessel lumen and
the interstitial space and contributes to the modulation of
inflammation and coagulation, but also regulates blood
pressure, vascular tone and blood flow by the release of a
large number of vasodilating substances such as nitric
oxide (NO) and prostacyclin (PGI2) and of vasoconstric-
tors such as endothelin (ET) and platelet factor (platelet-
activating factor (PAF)) [105-107]. In addition to its role
as a vasodilator, there are a number of other biologically
important effects of NO: NO improves the perfusion of
the coronary arteries and the cardiovascular system. It
can lead to swelling of the corpus cavernosum of the
penis and can relax the vascular muscle and the bronchial
tree. NO is released from the endothelial cells and inhi-
bits prostacyclin in combination with the aggregation of
platelets [108]. Nitric oxide (NO) is present in almost
every organ system and is produced by the endothelial
NO synthase by the cleavage of the amino acid L-arginine.
Because of its short half-life, it is generated directly in
the target area. eNOS is expressed mainly by thevascular endothelial cells of the tunica media of the ar-
terial blood vessels. Its production is influenced by vari-
ous physiological and pathophysiological stimuli
[109,110]. The expression of eNOS is regulated at the
transcriptional and at the posttranscriptional level.
Meanwhile, several physiological and pathophysiological
stimuli, influencing the transcription of the eNOS gene,
are known: Thus, the mRNA expression of eNOS is sig-
nificantly increased in response to lysophosphatidylcho-
line, shear stress and TGF-beta [111]. The eNOS mRNA
level not only depends on the transcriptional activity at
the promoter level, [111]. the post-transcriptional
modulation of the eNOS mRNA half-life is probably the
determining factor that influences the actual amount of
eNOS mRNA. eNOS mRNA can be stabilized through ex-
posure of endothelial cells to 3-hydroxy-3-methylglutaryl
(HMG)-CoA reductase inhibitors, [112] the VEGF or the
exposure to shear stress [113,114].
TNF-alpha, [115] oxLDL, [116] hypoxia, [116] and cell
confluence, [116] however, accelerate the degradation of
eNOS mRNA. The expression of eNOS mRNA is patho-
logical in a variety of vascular disorders [111]. A decrease
of the expression of eNOS mRNA has been described in
cardiovascular diseases [54].
The half-life and biological activity of NO is decisively
affected by reactive oxygen derivatives (ROS), such as O2
[117,118] O2 and nitric oxide (NO) are important sub-
strates as to the regulation of vasodilation and vasocon-
striction. These small molecules exhibit opposing effects
on the vascular tone and result in the production of po-
tentially toxic substances, such as peroxynitrite (ONOO-
) [119-125]. The endothelial bioavailability of NO in ath-
erosclerosis and in heart failure is reduced through a
decreased activity of antioxidant enzyme systems
(ecSOD= extracellular superoxide dismutase) and
increased activity of oxygen radical-producing enzyme
systems (NADPH oxidase, xanthine oxidase). In endo-
thelial cells and in vascular smooth muscle cells, this
membrane-associated, NAD(P)H-dependent oxidase is
the most important O2-producing enzyme in endothelial
cells, smooth muscle cells and/or vascular adventitia.
There may be a link between the NAD(P)H- dependent
oxidase NAD, being required by sirtuins. It is reported
that the eNOS activity can be reduced by HDAC inhibi-
tors, resulting in an impaired relaxation of blood vessels
[52].
In summary, the endothelium-dependent vasoregulation
depends on the interplay between opposing vasoconstrict-
ive (e.g. plasma endothelin-1 (EDN1), thromboxane
(TXA2), methyl arginine, transcription factor HIF-1α and
acetylcholine), and vasodilating activities (e.g. prostaglan-
dins (prostacyclin), CGRP (calcitonin gene related pep-
tide) and the endothelial isoform of nitric oxide synthase
(eNOS, synonym: NOS3)) [102-104].
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MicroRNAs (miRNAs) belong to the group of non-coding
RNAs and work as regulators of gene expression at the
mRNA level by suppression of translation and finally deg-
radation of mRNAs for example by Ago2 mediated cleavage
[38]. The expression profile of miRNAs in a rat model of
vascular restenosis showed that 100 out of 140 miRNAs
were differentially regulated during neointima reformation.
In this context miRNA 21 was identified to be a key regula-
tor of cell proliferation and the redifferentiation of smooth
muscle cells (SMCs) [126]. Downregulation of miRNA 145
and miRNA 143 after vascular injury modulates the SMC
cytoskeleton at least in part by induction of KLF5, which
further reduces SMC contractility. SMC proliferation is –
among other things - enhanced by the downregulation of
cell cycle inhibitors such as p27 and p57 and by increased
endogenous levels of miRNA 221 and miRNA 222 [127].
The inflammation of vessel walls during the development of
atherosclerosis is enforced by the downregulation of miRNA
126 which promotes the expression of VCAM-1 on one
hand, while it induces the production of CXCL12 on the
other leading to the recruitment and adhesion of inflamma-
tory cells [128,129]. As reported by Menghini et al. an
increased expression of miRNA 217 in atherosclerotic pla-
ques in patients leads to the disintegration of the endothe-
lium and thus to the acceleration of vascular senescence via
inhibition of SIRT1 [130]. Since miRNAs appear to be of ut-
most importance in the pathogenesis of cardiovascular dis-
ease, the profiling of circulating miRNAs might be a useful
biomarker for disease assessment [131]. Fichtlscherer et al.
confirmed the reduction of circulating miRNA 126 and
miRNA 145 amongst others in the serum of patients with
coronary artery disease [132]. Other miRNAs that qualify as
biomarkers are miRNA 1, miRNA 133b and miRNA 499
which have been shown to be elevated in patients and ani-
mal models of acute myocardial infarction [133,134].
LncRNAs, non-coding RNAs with more than 200
nucleotides, are transcribed as overlapping sense and
anti-sense transcripts to coding DNA regions regulating
the transcription of corresponding overlapping mRNA
[38]. Robb and colleagues found evidence for the regula-
tion of eNOS expression by overlapping antisense
lncRNA, [135] which was upregulated during hypoxia
[136]. Also, hypoxia induces the antisense transcript to
the 3′ UTR of HIF −1α which is similarly expressed in
renal cancer and different human tissues [137,138].
Non-conding RNAs play a pivotal role in the patho-
genesis of cardiovascular disease and offer the possibility
to operate as diagnostic and prognostic biomarkers.
Perspectives for treatment and prevention
Unaltered epigenetic regulation pathways like DNA
methylation, posttranslational chromatin modifications
and ncRNAs provide the basis for healthy cardiovascularsystem. By now, many studies show positive effects and
possibilities of treatment via epigenetic modulators.
Based on these experiences therapeutic intervention of
hypoxia associated diseases like asthma and chronic ob-
structive pulmonary disease as well as of inflammatory
processes by modulation of epigenetic factors seems to
be promising.
Nutritional factors are highly essential in the preven-
tion of cardiovascular disease and comprise both, the
avoidance of unfavourable food supplements such as
high concentrations of low density lipoproteins and salt
as well as the accentuation of beneficial effects of nu-
tritional ingredients such as folic acid or resveratrol
[139-143].
In 1993 Frankel et al. identified antioxidative effects
for resveratrol (3,4′,5-trihydroxystilbene) on low density
lipoproteins (LDLs) thus reducing a crucial initiation
event in the pathogenesis of atherosclerosis [144]. In
addition, Wallerath et al. found evidence of resveratrol
enhancing the activity and expression of eNOS in vitro
[145]. In 2006, resveratrol, which is a plant derived acti-
vator of SIRT1, was found to decrease reactive oxygen
species, inflammation, and apoptosis in the aortas of eld-
erly mice that ran through a high-fat diet. Resveratrol is
known to maintain normal endothelial function [146]. In
transgenic apolipoprotein E null mice overexpression of
SIRT1 was reported to reduce atherosclerosis due to
increased endothelial cell survival and function [147]. In
addition, SIRT1 was demonstrated to prevent excessive
superoxide production and to reduce inflammation
through inhibition of NFκB signalling and a reduction of
ICAM-1 and VCAM-1 expression levels [148]. SIRT1
also induces and directly enhances the expression of
eNOS, which decreases the speed of vascular senesce.
The activation of SIRT1 therefore appears to be an im-
portant tool as to the therapy of cardiovascular disease.
[149,150] The regulation of SIRT3 is closely connected
to SIRT1 and seems to protect against damage caused by
myocardial infarction or chronic heart failure [151].
Resveratrol is a plant derived factor that is mainly found
in berries, grape skin and red wine and was the first acti-
vator of SIRT1 to be identified [145]. Very recently it
was shown in a mouse model that resveratrol prevents
diet induced left ventricular hypertrophy as well as inter-
stitial fibrosis and diastolic dysfunction {Qin, 2012
#16820}. Resveratrol represents the tip of the iceberg
when it comes to the effects of nutrition on the epigen-
ome and thus, their role in the prevention and pathogen-
esis of cardiovascular disease.
Folates are part of the family of water-soluble B vitamins,
which directly serve the one-carbon-metabolism with me-
thionine for the production of S-adenosylmethionine. This
in turn is the one-carbon-donor for the methylation of
DNA [152]. Folic acid deficiency leads to global DNA
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for cancer and cardiovascular disease [70,139]. During the
course of atherosclerosis smooth muscle cells transform
and share a number of characteristic similarities with cancer
cells such as the overexpression of proto-oncogenes,
growth-factors as well as increased cell motility [142]. This
transformation is based on the global hypomethylation of
DNA. Accordingly, at the age of four weeks ApoE mice
show changes in the DNA methylation pattern prior to the
generation of atherosclerotic lesions [153]. Similarly, a re-
duction of~9% in C5-methylation was identified in
advanced atherosclerotic plaques in humans [154]. Folic
acid directly influences the function of vascular endothelial
cells via improving NO production and vasodilation. Doshi
et al. for example showed improvement of endothelial func-
tion in CVD patients after intervention with homocysteine
{Doshi, 2002 #16819}.
Resveratrol and B vitamins prove to be important both,
in the prevention and the treatment of cardiovascular
disease and carry the advantage of being practically free
of side effects. Currently more than hundred clinical
trials are ongoing or already completed studying the
aspects of resveratrol or folate administration in subjects
thus emphasizing their relevance for prevention of diet
induced CVDs in humans (ClinicalTrials.gov).
In addition to nutritional factors a number of small
molecule HDAC inhibitors for the treatment of cardio-
vascular disease are currently available:
In preclinical studies, most of the small molecule inhi-
bitors of HDACS are hydroxamid acid derivates like the
pan-HDAC inhibitor TSA and suberoylanilide hydroxa-
mic acid (SAHA) [8].
HDAC inhibitors (HDACIs) are potential candidates in
the treatment of cardiovascular disease such as cardiac
hypertrophy, heart failure, ischemia/reperfusion injury,
atherosclerosis and restenosis [155,156], Gallo et al. for
example demonstrated in a mice model that the selective
inhibition of class I HDACs with an apicidin derivate
prevented cardiac hypertrophy and failure [157]. Raja-
singh et al. treated mouse bone marrow progenitor cells
with TSA and 5-Aza and further differentiated these cells
into myocyte progenitors. The implantation of these cells
led to an improvement of cardiac function after infarc-
tion. This points out another route small molecules
unclose for CVD treatment {Rajasingh, 2011 #16828}. In
recent in vitro experiments TSA was shown to agonist
load- and agonist-induced hypertrophy which suppressed
autophagy of myocytes. These data where supported by
the finding that the ventricular mass of hypertrophic ani-
mals was normalized as well as ventricular function
{Cao, 2011 #16832}.
In the treatment of AAA, there have recently been
new results: Metacept-1 (MCT-1), a synthetic derivate of
oxamflavin, also serves as an inhibitor of HDAC andshowed AAA inhibitory effects in a mouse model [158].
HDAC inhibitors seem to constitute a potential way of
managing AAA by targeting aortic proteolytic degradation.
Conclusions
In summary, class II and class III HDACs where shown
to exert heart protective activities [95]. Further investiga-
tions are crucial to get a better understanding of the
complex epigenetic interactions and to provide new ways
for the treatment of vascular disease.
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